RecruitingPhase 3NCT06859788

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease

Sponsor

Sound Pharmaceuticals, Incorporated

Enrollment

200 participants

Start Date

Oct 29, 2025

Study Type

INTERVENTIONAL

Conditions

Meniere's Disease Ménière's Disease

Summary

Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ebselen for people with meniere's disease and ménière's disease. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEbselen

Glutathione peroxidase mimetic

Locations(9)

The House Institute

Los Angeles, California, United States

ENT and Allergy Associates of Florida

Boynton Beach, Florida, United States

ENT and Allergy Associates of Florida

Delray Beach, Florida, United States

Northwell Health

New Hyde Park, New York, United States

ENT and Allergy Associates, LLP

New York, New York, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Medical University of South Carolina

Charleston, South Carolina, United States

University of Texas Southwestern

Dallas, Texas, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06859788

Related Trials

Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets

NCT048062821 location

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT035877011 location

Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes

NCT075180691 location

Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation

NCT060015931 location